Valsartan-Teva is a widely used therapeutic option generally used to provide sustained therapeutic support in multiple clinical scenarios, focusing on therapeutic support during conditions marked by increased physiological stress. Its therapeutic applications are relevant for three main areas.

---

Therapeutic Scope and Benefits

Valsartan is commonly used to provide supportive relief in conditions characterized by systemic imbalance, including long-term supportive relief in conditions marked by essential hypertension (high blood pressure) in adults and children 1 year and older. It is also applied in patients with chronic heart failure (NYHA class II-IV) and utilized for supportive relief during phases following an acute myocardial infarction when complicated by left ventricular dysfunction.

The medication helps manage symptom clusters that may become intense or disruptive, such as excessive fluid retention (edema) and exertional shortness of breath associated with heart failure. The therapeutic benefit is relevant for easing symptoms related to systemic imbalance, which lessens the overall burden on the circulatory system and contributes to easing the overall symptom load related to systemic imbalance. Furthermore, it is relevant in conditions involving systemic imbalance, where it provides therapeutic support to the kidneys in diabetic patients with hypertension.

Quick Fact: Relief for Cardiac Overload
Valsartan supports the patient during difficult heart failure episodes and assists with maintaining functional stability and helps improve day-to-day comfort during symptomatic periods.

Regulatory References

1. NIH DailyMed official information

Who Can and Cannot Use Valsartan-Teva?

Population eligibility for Valsartan-Teva is strictly defined by official regulatory labeling, outlining specific groups who are allowed to use the medicine and those who are formally prohibited.

Absolute Contraindications

Valsartan-Teva must not be used in certain populations where the risk is officially deemed unacceptable:

• Pregnancy: The medicine is strictly contraindicated during the second and third trimesters due to the high risk of fetal toxicity. Discontinuation is mandatory immediately upon pregnancy detection.
• Severe Hepatic Impairment: Patients with severe liver disease, including biliary cirrhosis and cholestasis, are contraindicated.
• Hypersensitivity: Use is barred for individuals with a known allergy to the active substance valsartan or any of its excipients.
• Dual Therapy: Diabetic patients concurrently using medications containing aliskiren are strictly contraindicated.

Population-Specific Restrictions and Eligibility

Group	Eligibility Status
Adults (18+ years)	Approved for all labeled indications.
Pediatrics (6-18 years)	Approved only for hypertension; use for heart failure is not established.
Children (<6 years)	Not recommended for hypertension treatment.
Severe Renal Impairment	Not recommended for patients with a GFR <30 mL/min.
Lactation	Not recommended for breastfeeding women.
Mild-to-Moderate Hepatic Impairment	Use is restricted and requires specific dose limitations.

Official eligibility for this Angiotensin II Receptor Blocker (ARB) is strictly classified based on these criteria, ensuring its use remains within established safety parameters defined by global health authorities.

Valsartan-Teva's official interaction profile is defined by combinations that may significantly affect electrolyte balance and kidney function. A principal restriction is the contraindication of co-administration with Aliskiren in patients with pre-existing Diabetes Mellitus or documented Renal Impairment. This rule addresses the increased risks of severe hypotension, hyperkalemia, and kidney function changes associated with Dual Blockade of the Renin-Angiotensin System (RAS).

Interactions involving Potassium-sparing diuretics, Potassium supplements, and potassium-containing salt substitutes are officially restricted due to the combined risk of developing clinically significant hyperkalemia. Concurrent use with Angiotensin-Converting Enzyme (ACE) Inhibitors also contributes to the Dual RAS Blockade risk.

Furthermore, co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, may attenuate the blood pressure-lowering effect and increase the risk of acute renal function deterioration, a risk that is explicitly noted as being higher in the elderly and in volume-depleted patients.

Valsartan also affects the elimination of certain other medicines. Concurrent use with Lithium can reduce its renal clearance, leading to increased serum lithium concentrations and the potential for toxicity.

Valsartan-Teva functions as a selective angiotensin II receptor blocker (ARB). Its primary biological target is the angiotensin II type 1 ( AT1) receptor, which is a G q-protein coupled receptor expressed in various tissues, including vascular smooth muscle and the adrenal gland. Valsartan acts as an antagonist, binding with high affinity to the AT1 receptor and preventing the binding and subsequent signaling of the endogenous ligand, angiotensin II.

This blockade inhibits the normal intracellular pathways triggered by angiotensin II, such as the G q protein cascade leading to the activation of phospholipase C and subsequent increase in intracellular calcium ( Ca^2+) concentration. Downstream, the inhibition of AT1 signaling suppresses vasoconstriction and the synthesis and secretion of aldosterone from the adrenal cortex.

At the system level, this pharmacodynamic action results in generalized peripheral vasodilation and a reduction in sodium and water retention. Valsartan's blockade of the AT1 receptor also removes the negative feedback on the renin-angiotensin-aldosterone system (RAAS), causing a compensatory rise in plasma renin activity and circulating angiotensin II levels, which may then stimulate the unblocked AT2 receptor.

How to Use Valsartan-Teva: Official Administration Guidelines

Valsartan-Teva, containing the active ingredient Valsartan, is administered exclusively via the oral route using a film-coated tablet. This medication is generally intended for long-term maintenance therapy in chronic cardiovascular conditions. The tablets must be swallowed whole, and administration may occur with or without food.

Dosing Patterns and Frequency

Official dosing schedules vary based on the specific clinical application. For the management of hypertension, the typical starting dose is 80 mg or 160 mg once daily, with a usual maintenance range up to 320 mg once daily. For supportive management of heart failure, the medicine is started at a lower dose of 40 mg and taken twice daily (BID), with titration aiming for a target maximum of 160 mg BID. Dosing adjustments, or titration, are typically conducted after a period of 2 to 4 weeks, allowing the therapeutic response to stabilize.

Special Administration Conditions

• Missed Dose: If a scheduled dose is missed, the dose is skipped and the next dose is taken at the regular time, rather than taking a double dose.
• Hepatic Impairment: For patients with mild-to-moderate liver impairment (without cholestasis), a specific dosage constraint exists, and the dose generally should not exceed 80 mg once daily.
• Pediatric Use: For hypertensive children 6 to 16 years of age, the dosing is calculated based on weight, starting at 1.3 mg/kg once daily. In specific contexts, an oral suspension can be compounded from tablets for proper administration.

Overview of Clinical Research

The Valsartan substance was studied across multiple phases of research. Research has evaluated its effect on symptoms associated with chronic conditions. Clinical trials examined its profile in various patient groups. It is not yet clear whether a longer treatment duration affects outcomes, and evidence remains limited regarding the long-term changes research has explored.

Key Study Areas

Research into Symptom Management

Findings from studies explored whether the substance could be used in the management of chronic conditions. Research investigated the substance for various endpoints, including general wellbeing and functional status.

• Dosing: Several Phase II trials evaluated whether different dosages of the drug were associated with changes in symptom severity over a 12-week period. Findings were mixed regarding the optimal dose to maintain a stable condition.
• Symptom Reduction: One large meta-analysis examined whether the substance was associated with changes in pain and inflammation in patients with condition A. The analysis evaluated whether there was a change in inflammatory markers over six months.
• Combination Therapies: Research has explored whether the combination affects specific biological markers when administered with standard-of-care medication. The studies specifically evaluated the co-administration's impact on systemic absorption.

Safety Profile and Adverse Events

Studies evaluated the treatment's safety profile in over 500 participants across three countries. In the reviewed studies, the most frequently reported adverse events (AEs) involved gastrointestinal discomfort and localized skin reactions.

• Long-Term Safety: No Phase IV registry data is available to draw conclusions on long-term safety. Data is not yet sufficient to evaluate rare, late-onset adverse effects.
• Drug-Drug Interactions: Preliminary in-vitro studies suggested that the substance may interact with cytochrome P450 enzymes. Researchers have not yet fully determined the clinical relevance of these in-vitro findings.
• Contraindications: The research did not address whether specific populations, such as people with pre-existing liver conditions, should avoid this substance. The evidence does not offer guidance on when to consult a healthcare provider regarding potential interactions.

Comparison to Other Approaches

Research investigated different approaches to symptom management, including lifestyle changes, over-the-counter medication, and the substance under study. The studies examined subjective patient reports of symptom control and quality of life. The data did not include a direct comparison to all currently approved prescription therapies.

Common questions about Valsartan-Teva (FAQ)

Q: What is the main reason Valsartan-Teva is prescribed?

According to official indications, the medicine is primarily prescribed for the treatment of high blood pressure and heart failure. It is also indicated for reducing the risk of cardiovascular mortality in certain patients following a heart attack.

Q: Is Valsartan-Teva a type of blood pressure medicine?

Yes, regulatory documents state that Valsartan is a medication used to treat hypertension, which is the term for high blood pressure. Its primary function is to help lower blood pressure in patients who are prescribed it.

Q: Can Valsartan-Teva be used for conditions other than high blood pressure?

Official product information confirms that Valsartan is also indicated for use in certain patients with heart failure. Additionally, it is used for reducing the risk of cardiovascular mortality following a heart attack.

Q: How does the medicine Valsartan work in the body?

Valsartan is officially classified as an Angiotensin II Receptor Blocker (ARB). It works by blocking the effects of a hormone called Angiotensin II, which helps to relax blood vessels.

Q: How long does it typically take to see the effect of Valsartan-Teva?

For patients taking Valsartan for hypertension, studies indicate that the blood pressure-lowering effect is substantially present within two weeks. The maximum reduction in blood pressure is generally attained after four weeks of treatment.

Q: What does the research say about Valsartan-Teva's duration of action?

Pharmacodynamic studies cited in official documents describe that a single dose of Valsartan can provide an effect that persists for 24 hours. This information supports the typical once-daily dosing pattern for the medication.

Q: What is the general information about Valsartan-Teva use for heart failure?

Official product information indicates that Valsartan is used to help reduce the risk of hospitalization for certain patients who have heart failure. This application is often noted for patients with specific classifications of heart failure (NYHA class II–IV).

Q: Why is Valsartan-Teva sometimes prescribed after a heart attack?

Valsartan is officially indicated for use in clinically stable patients who have experienced a heart attack. The purpose is to reduce the risk of cardiovascular mortality in those patients who have left ventricular failure or dysfunction.

Q: What is the evidence theme regarding Valsartan-Teva for reducing stroke risk?

Official prescribing information states that in patients with high blood pressure, lowering blood pressure with Valsartan is associated with a reduction in the risk of cardiovascular events. This includes a reduction in the risk of both fatal and nonfatal strokes and heart attacks.

Q: What kind of studies have been done on Valsartan-Teva?

Official documents cite clinical studies that have specifically examined the use of Valsartan for its three main indications: hypertension, heart failure, and use following myocardial infarction (heart attack). These studies establish the evidence themes for the drug's use.

Q: Is Valsartan-Teva the same as just Valsartan?

Valsartan is the name of the active drug ingredient itself, which is the component responsible for the therapeutic effect. The addition of '-Teva' indicates that the product is manufactured or marketed by Teva Pharmaceuticals, which is common for generic versions of a medication.

Q: What is the difference between Valsartan-Teva and Diovan?

Valsartan is the generic name of the active compound, while Diovan is a major brand name under which Valsartan has historically been marketed. Both contain the same active medicinal ingredient.

Q: Is Valsartan-Teva available as a generic medicine?

Valsartan is the generic name of the active ingredient, and it is widely available as a generic medication. The generic availability is determined by market regulatory approval after brand name patent expiration.

Q: Is Valsartan-Teva a diuretic (water pill)?

Valsartan is officially classified as an Angiotensin II Receptor Blocker (ARB). It belongs to a different drug class than diuretics, which are commonly referred to as a water pill.

Q: Is Valsartan-Teva a statin?

Valsartan is officially classified as an Angiotensin II Receptor Blockers (ARB). It belongs to a different drug class than statins, which are used to lower cholesterol.

Q: Are there different strengths of Valsartan-Teva tablets?

Yes, the official documentation describes that Valsartan is available in various tablet strengths. This allows healthcare providers to tailor the dosage based on the prescribed condition and individual needs.

Q: Is Valsartan-Teva often prescribed alongside other blood pressure medications?

Official prescribing information states that Valsartan may be used alone or in combination with other medicines for the treatment of high blood pressure.

Q: Can older people generally use Valsartan-Teva?

Official sources have not generally identified geriatric-specific problems that would place limitations on the use of Valsartan in older adults.

Q: Are there any age restrictions mentioned in official documents for Valsartan-Teva?

Regulatory documents state that Valsartan is indicated for the treatment of hypertension in adults and pediatric patients aged 6 years and older. Its use is generally not recommended for children younger than 6 years of age.

Q: What does research suggest about Valsartan-Teva's use in younger adults?

Official prescribing information for Valsartan covers its use for hypertension in patients 6 years of age and older. This includes the use of the medicine in the general adult population.

Q: Can people with diabetes generally use Valsartan-Teva?

Official warnings specify that the combination of Valsartan and the drug aliskiren is generally advised against for patients who have diabetes. However, it is not generally contraindicated for all patients with diabetes when used as a single agent or with other appropriate medications.

Q: Are there specific populations for whom Valsartan-Teva is described as less suitable?

Official warnings indicate that the use of Valsartan is generally contraindicated for patients who are pregnant. Furthermore, regulatory information advises against the re-administration of Valsartan to patients who have previously experienced a severe allergic reaction, such as angioedema.

Q: Are there specific official safety warnings about using Valsartan-Teva during pregnancy?

Yes, the US official prescribing information contains a boxed warning about fetal toxicity related to the use of Valsartan. Official warnings state that the medicine is generally recommended to be discontinued as soon as a pregnancy is confirmed.

Q: Does Valsartan-Teva have an official 'black box warning' in the US?

Yes, the US official prescribing information contains a boxed warning, sometimes called a Black Box Warning. This warning is in place due to the risk of fetal toxicity during pregnancy.

Q: Is swelling of the face or throat an officially noted serious side effect?

Yes, angioedema (swelling of the face, lips, pharynx, or tongue) has been reported in postmarketing experience. Official product information notes this as a potentially serious adverse reaction.

Q: Are there any specific official warnings for people with angioedema history using Valsartan-Teva?

Official warnings describe that re-administration of Valsartan is generally advised against for patients who have previously experienced angioedema (severe swelling) while taking it.

Q: Does Valsartan-Teva have a known effect on kidney function?

Official warnings describe that impaired renal function (kidney function problems) and renal failure have been reported in postmarketing experience. Official information includes warnings regarding caution for use in patients who already have impaired renal function.

Q: Is it necessary to have routine blood tests while using Valsartan-Teva?

Because of the drug's potential effects on kidney function and potassium levels, regulatory warnings describe that periodic laboratory monitoring may be necessary for some patients.

Q: What are the official sources describing about overdose symptoms with Valsartan-Teva?

Official sources describe that the most likely symptom of an overdose is anticipated to be hypotension, which is very low blood pressure. This severe drop in blood pressure may result in side effects such as dizziness or fainting.

Q: What are some common mild side effects that patients report?

Official product information lists common side effects, which may include headache, dizziness, viral infection, and abdominal pain.

Q: What are the official sources saying about Valsartan-Teva and dizziness?

Dizziness is listed in official documents as one of the commonly reported side effects observed in clinical trials for Valsartan across its various indications.

Q: Is it common to feel tired when first starting Valsartan-Teva?

Official documentation lists fatigue as one of the side effects that was commonly reported in clinical trials for both the hypertension and heart failure indications.

Q: Is a persistent dry cough associated with Valsartan-Teva?

A cough has been noted as an adverse reaction in official prescribing information for Valsartan.

Q: Can Valsartan-Teva cause stomach upset?

Official documents note that stomach upset is possible; for instance, abdominal pain and diarrhea are listed as common adverse reactions for Valsartan.

Q: Does Valsartan-Teva interact with common pain relievers like ibuprofen?

Regulatory warnings state that the use of non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, may present a potential interaction. This interaction may increase the risk of certain kidney problems and could potentially reduce the blood pressure-lowering effects of Valsartan.

Q: What foods or drinks are commonly mentioned as having potential interactions with Valsartan-Teva?

Official warnings describe that there is a potential interaction risk with potassium-containing salt substitutes and potassium supplements. Using these products while on Valsartan may lead to increases in the body's potassium levels.

Q: Can Valsartan-Teva affect my potassium levels?

Yes, official product information states that Valsartan is associated with a potential for an increase in serum potassium levels. This condition, known as hyperkalemia, is noted as a common adverse reaction in certain patient groups, such as those with heart failure.

Q: What kind of interactions are listed for Valsartan-Teva and supplements?

Official warnings include that potassium supplements may interact with Valsartan. This interaction can potentially lead to high serum potassium levels.

Q: What is the general rule about using salt substitutes while on Valsartan-Teva?

Official warnings indicate that the use of salt substitutes that contain potassium is generally advised against due to the potential for interaction. The use of such products can increase the risk of developing high serum potassium levels, known as hyperkalemia.

Q: What information is available regarding Valsartan-Teva and alcohol consumption?

Official sources note that alcohol consumption may increase the blood pressure-lowering effect of Valsartan. This increased effect can raise the risk of experiencing side effects such as dizziness or light-headedness.

Q: Do lifestyle factors, like exercise, still matter when taking Valsartan-Teva?

Official prescribing information states that managing blood pressure with Valsartan is part of a comprehensive cardiovascular risk management plan. This plan often includes lifestyle measures such as exercise and controlled sodium intake.

How to Store and Dispose of Valsartan-Teva (Tablet)

Official regulatory guidelines strictly define the conditions for storing and disposing of Valsartan-Teva tablets to ensure stability and public safety.

---

Storage Requirements

Condition	Requirement
Temperature	Store at room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection	Keep in the original container and maintain it tightly closed to protect the contents from moisture and light.
Child Safety	Mandatory to keep the medicine out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Valsartan-Teva must be disposed of according to local regulations and official drug take-back programs. The medicine must not be disposed of via wastewater or household waste, as instructed in official regulatory documents.